The study data is still being analysed and detailed results are planned to be presented at a conference in
2009. The manufacturers, Novartis, hope to submit the drug for licensing by the end of 2009.
Pam Macfarlane, Chief Executive of the MS Trust said, "We welcome the positive results of the study. However, these are early results from a study looking at a short period of treatment.